

1 **Head-to head comparison of anterior nares and nasopharyngeal swabs for SARS-CoV-2**
2 **antigen detection in a community drive-through test centre in the UK**

3

4 Rachel L Byrne¹, Ghaith Aljayyousi¹, Konstantina Kontogianni¹, Karina Clerkin¹, Mathew
5 McIntyre¹, Jahanara Wardale¹, Christopher T Williams¹, CONDOR steering group, Richard
6 Body², Emily R Adams^{1,3}, Margaretha de Vos⁴, Camille Escadafal⁴, Ana I Cubas Atienzar¹.

7

8 ¹Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK

9 ² Manchester University NHS Foundation Trust, UK

10 ³Global Access Diagnostics, Bedfordshire, UK

11 ⁴FIND, Geneva, Switzerland

12

13 * Corresponding author Ana I Cubas Atienzar Ana.CubasAtienzar@lstmed.ac.uk

14

15 Keywords: SARS-CoV-2, COVID-19, Nasal swabs, nasopharyngeal swabs, antigen detection,

16 RDT, LFA, head-to-head comparison.

17 **Abstract:**

18 **Objective:** To conduct a head-to-head diagnostic accuracy evaluation of professionally taken
19 anterior nares (AN) and nasopharyngeal (NP) swabs for SARS-CoV-2 antigen detection using
20 rapid diagnostic tests (Ag-RDT).

21 **Methods:** NP swabs for SARS-CoV-2 reverse transcription quantitative polymerase chain
22 reaction (RT-qPCR) testing and paired AN and NP swabs for the antigen detection were
23 collected from symptomatic participants enrolled at a community drive-through COVID-19
24 test centre in Liverpool. Two Ag-RDT brands were evaluated: Sure-Status (PMC, India) and
25 Biocredit (RapiGEN, South Korea). The visual read out of the Ag-RDT test band was
26 quantitative scored and the 50% and 95% limit of detection (LoD) of both Ag-RDT brands
27 using AN and NP swabs was calculated using a probabilistic logistic regression model.

28 **Results:** A total of 604 participants were recruited of which 241 (40.3%) were SARS-CoV-2
29 positive by RT-qPCR. Sensitivity and specificity of AN swabs was equivalent to the obtained
30 with NP swabs: 83.2% (75.2-89.4%) and 98.8% (96.5-99.6%) utilising NP swabs and 84.0%
31 (76.2-90.1%) and 99.2% (97.0-99.8%) with AN swabs for Sure-Status and; 81.2% (73.1-
32 87.7%) and 99.0% (94.7-86.5%) with NP swabs and 79.5% (71.3-86.3%) and 100% (96.5-
33 100%) with AN swabs for Biocredit. The agreement of the AN and NP swabs was high for
34 both brands with an inter-rater reliability (κ) of 0.918 and 0.833 for Sure-Status and
35 Biocredit, respectively. The overall 50% LoD and 95% LoD was $0.9-2.4 \times 10^4$ and $3.0-3.2 \times 10^8$
36 RNA copies/mL for NP swabs and $0.3- 1.1 \times 10^5$ and $0.7-7.9 \times 10^7$ RNA copies/mL and for AN
37 swabs with no significant difference on LoD for any of the swabs types or test brands.
38 Quantitative read-out of test line intensity was more often higher when using NP swabs
39 with significantly higher scores for both Ag-RDT brands.

40 **Conclusions:** the diagnostic accuracy of the two SARS-CoV-2 Ag-RDTs brands evaluated in
41 this study was equivalent using AN swabs than NP swabs. However, test line intensity was
42 lower when using AN swabs which could influence negatively the interpretation of the Ag-
43 RDT results for lay users. Studies on Ag-RDT self-interpretation using AN and NP swabs are
44 needed to ensure accurate test use in the wider community.

45 **Abstract word count: 345**

46

47 **Introduction**

48 To meet the immense diagnostic demand of the COVID-19 pandemic, the development of
49 rapid diagnostic tests for the detection of SARS-CoV-2 antigens (Ag-RDTs) became a priority
50 [1]. Nasopharyngeal (NP) swabs are considered the standard of care for SARS-CoV-2
51 detection[2] and thus the majority of Ag-RDT kits are developed for NP swabs exclusively
52 [1]. However, the use of anterior nasal (AN) swabs has been increasing as a less invasive
53 alternative to promote access to testing in the community and facilitate mass testing
54 programmes particularly in the UK [3].

55 For Ag-RDTs, studies on Ag-RDTs comparing sensitivity on AN swabs and NP swabs are very
56 limited, with only two reported studies performed on the same Ag-RDT brand, Standard-Q
57 (SD Biosensor, Inc., Korea), one study on professional taken swabs [6] and another in self-
58 taken [7]. Sensitivity obtained with AN swabs was comparable (although 3% to 5% lower)
59 than with NP swabs sensitivity but neither of the swab types fulfilled WHO target product
60 profile (TPP) standards in any of the two studies [8]. AN swabs are considered accurate and
61 clinically acceptable alternatives to NP swabs in outpatient settings for SARS-CoV-2 reverse
62 transcription polymerase chain reaction (RT-PCR) testing [4]. However, an in depth
63 metaanalysis on SARS-CoV-2 RT-PCR testing found that anterior nares specimens were 12%-
64 18% less sensitive than NP swabs [5].

65 The aim of this study was to perform a head-to-head evaluation on two World Health
66 Organisation (WHO) approved or under assessment for Emergency Use listing (WHO-EUL)
67 SARS-CoV-2 Ag-RDT brands marketed for AN and NP swabs: Sure-Status COVID-19 Antigen
68 Card Test (Premier Medical Corporation, India) and Biocredit COVID-19 Antigen Test
69 (RapiGEN, South Korea) respectively. This study is of particular interest in the UK as the use

70 of home Ag-RDTs on AN swabs has been integral to combatting the spread of COVID-19
71 during the pandemic [3], as on the 1st of April 2022 free national RT-PCR COVID-19 testing
72 was suspended, with the purchase of Ag-RDTs using AN-swabs online or in pharmacies the
73 only approach to access COVID-19 testing in a non-clinical setting.

74 **Methods**

75 **Clinical evaluation**

76 This was a prospective evaluation of consecutive participants enrolled at a community
77 National Health Service (NHS) drive-through COVID-19 test centre located at the Liverpool
78 John Lennon Airport. Two Ag-RDT brands were evaluated; Sure-Status COVID-19 Antigen
79 Card Test (Premier Medical Corporation India) and Biocredit COVID-19 Antigen Test
80 (RapiGEN, South Korea) referred as Sure-Status and Biocredit thereafter. The study
81 progressed until at least 100 Ag-RDT positives using AN swabs in line with WHO's
82 requirements for evaluation of alternative sample type [10].

83 All adults over the age of 18 who attended the drive-through test centre with symptoms of
84 COVID-19 were asked to participate in the study. The symptoms included fever, cough,
85 shortness of breath, tight chest, chest pain, runny nose, sore throat, anosmia, ageusia,
86 headache, vomiting, abdominal pain, diarrhoea, confusion, rash, or tiredness. Participants
87 were recruited under the Facilitating Accelerated COVID-19 Diagnostics (FALCON) study
88 using verbal consent. Ethical approval was obtained from the National Research Ethics
89 Service and the Health Research Authority (IRAS ID:28422, clinical trial ID: NCT04408170).

90 Swabs were collected following the same process with the NP swab collected first in one
91 nostril and placed in Universal Transport Media (UTM) (Copan Diagnostics Inc, Italy) for the

92 reference RT-qPCR test. This was followed by the collection of two swabs to evaluate the
93 Ag-RDTs, first an NP swab in the other nostril and finally a AN swab in both nostrils following
94 the manufacturer's instructions for use (IFU). Samples were given a unique identification
95 code and transported within cooler bags to the Liverpool School of Tropical Medicine
96 (LSTM) where samples were processed in category level 3 (CL3) containment laboratory
97 upon arrival.

98 Sure-Status and Biocredit Ag-RDTs were carried out following their instructions for use (IFU).
99 The protocol for both Ag-RDT was the same when using AN and NP swabs. Results were
100 read by two operators, blinded to one another and if a discrepant result occurred, a third
101 operator acted as a tiebreaker. The visual read out of the Ag-RDT test band was scored on a
102 quantitative scale from 1 (weak positive) - 10 (strong positive). Ag-RDT results were
103 classified as invalid when the control line was absent.

104 RNA was extracted using the QIAamp® 96 Virus QIAcube® HT kit (Qiagen, Germany) on the
105 QIAcube® (Qiagen, Germany) and screened using TaqPath COVID-19 (ThermoFisher, UK) on
106 the QuantStudio 5™ thermocycler (ThermoFisher, UK), an internal extraction control was
107 incorporated before the lysis stage, as recommended by the manufacturer. SARS-CoV-2 RT-
108 qPCR result was considered (1) positive if any two of the three SARS-CoV-2 target genes (N
109 gene, ORF1ab and S gene) amplified with cycle threshold (Ct) \leq 40, (2) indeterminate if only
110 one SARS-CoV-2 gene amplified and (3) negative if the internal extraction control amplified
111 and the SARS-CoV-2 target genes did not. Samples with invalid RT-qPCR results (no
112 amplification of the internal extraction control) were re-extracted and re-run once. Viral
113 loads in UTM swabs were measured with a ten-fold serial dilution standard curve of

114 quantified specific in vitro-transcribed RNA using five replicates for each standard curve
115 point [11].

116 **Statistical Analysis**

117 Sensitivity, specificity, positive predicted value (PPV) and negative predictive values (NPV)
118 were calculated with 95% confidence intervals (CIs) by comparing the Ag-RDT results to the
119 RT-qPCR, as the reference standard. Sub-analyses of diagnostic performance were
120 performed by swab type (AN and NP), Ct-value ranges, onset of symptoms and vaccination
121 status using nonparametric statistics. The level of agreement between AN and NP swabs
122 was determined using Cohen's kappa (κ) [10]. The correlation between test line intensity
123 and viral loads were measured by Person correlation coefficient (r_p) [12] and to further
124 analyse Ag-RDT sensitivities, we used logistic regression, with RNA copy numbers of the RT-
125 qPCR NP swab and swab type (AN and NP) as independent variables and test outcomes as
126 the dependent variable, yielding detection probabilities for each viral load level. Statistical
127 analyses were performed using SPSS V.28.0, Epi Info V3.01 and R scripts. Statistical
128 significance was set at $P < 0.05$.

129 **Results**

130 Participant demographics

131 A total of 604 participants were recruited for this study, 372 recruited between August and
132 October 2021 were enrolled for the Sure-Status Ag-RDT evaluation and 232 recruited
133 between December 2021 and March 2022 were enrolled for the Biocredit Ag-RDT
134 evaluation. Details of the demographics of the population of study are found in Table 1. Our
135 study population had a mean age of 43 years (range 18-81, interquartile range [IQR] 33.0-

136 50.0), 348 (58%) were female and 566 were British (94%), with the remaining 36
137 participants being of other ethnic groups (n = 14), white background (n = 9), Asian (n = 8),
138 mix white and black backgrounds (n = 2) and Arab (n = 1). Three hundred and fourteen
139 participants of the 372 enrolled for the Sure-Status evaluation (84.4%) and 217 participants
140 of the 232 recruited for Biocredit (93.5%) received complete SARS-CoV-2 vaccination (2
141 doses). Additionally, 143 of the participants enrolled from December 2021 (61.6%) for the
142 Biocredit evaluation received a third dose as part of the UK booster roll out [13]. All
143 participants were symptomatic with a median onset of symptoms of 2 days (IQR 1-3). The
144 most common symptoms were cough (387, 64.3%), sore throat (232, 38.5%), headache
145 (203, 33.7%), fever (160, 26.6%), body aches (80, 13.3%) and runny nose (80, 13.3%) (Table
146 1).

147 Overall, 241 participants (40.3%, CI95% 36.3-44.4%) were SARS-CoV-2 positive by RT-qPCR,
148 6 had indeterminate RT-qPCR results and the remaining 355 were negative. Participants
149 with indeterminate RT-qPCR results were excluded from further analysis.

150 RT-qPCR positivity was significantly higher ($p < 0.05$) among the participants enrolled for the
151 Biocredit evaluation cohort (53.7%, CI95% 47-60.4%) during December 2021 and March
152 2022 which coincided with the Omicron wave in the UK [14] than among the participants
153 enrolled between August and October 2021 (32.1%, CI95% 27.4-37.1%) when Delta was the
154 dominant SARS-CoV-2 variant.

155 Diagnostic evaluation

156 *Sure Status*

157 The overall sensitivity and specificity for the Sure-Status Ag-RDT compared to RT-qPCR was
158 83.2% (CI95% 75.2-89.4%) and 98.8% (CI95% 96.5-99.6%) utilising NP swabs and 84.0%
159 (CI95% 76.2-90.1%) and 99.2% (CI95% 97.0-99.8%) with AN swabs. For individuals with Cts <
160 25, the sensitivity was 91.8% (CI95% 84.5-96.4%) and 93.8% (CI95% 87.2-97.7%) for NP and
161 AN-swabs respectively. Seven Ag-RDTs gave invalid results, one NP swab (0.03%) sample and
162 six AN swab samples (1.6%). Participants with invalid Ag-RDTs results were excluded from
163 further analysis. Four SARS-CoV-2 positive cases were detected by NP only (3.4%) and six
164 cases were detected by AN only (5.0%) but this discrepancy on sensitivity between swab
165 types was not significant ($P = 0.43$). The percentage of agreement of NP and AN swab using
166 Sure-Status was 96.7% (95% CI 94.3-98.3%) and inter-rater reliability was almost perfect ($\kappa =$
167 0.918). Inter-rater reliability was strong for both NP ($\kappa = 0.871$) and AN ($\kappa = 0.852$) swabs
168 when compared to RT-qPCR.

169 *Biocredit*

170 For the Biocredit Ag-RDT the sensitivity and specificity were 81.2% (CI95%73.1-87.7%) and
171 99.0% (CI95%94.7-86.5%) with NP swabs and 79.5% (CI95%71.3-86.3%) and 100%
172 (CI95%96.5-100%) with AN sampling compared to RT-qPCR. Sensitivity was 92.2%
173 (CI95%84.6-96.8%) and 95.5% (CI95%89.0-98.8%) using NP and AN swabs among
174 participants with Ct < 25. Ten SARS-CoV-2 positive cases were detected solely by NP (8.2%)
175 and eight cases were detected only by AN (6.6%) but no significance on sensitivity was
176 observed between NP and AN swabs for this brand of Ag-RDTs either ($P = 0.43$). The
177 percentage of agreement of NP and AN swab for Biocredit was 91.6% (95% CI 87.2-94.9%)
178 and inter-rater reliability was strong ($\kappa = 0.833$). Inter-rater reliability was moderate for both

179 NP ($\kappa = 0.790$) and AN ($\kappa = 0.782$) sampling compared to RT-qPCR. Diagnostic accuracy for
180 both Sure-Status and Biocredit is displayed in Table 2.

181 *Head to head comparison of Sure Status and Biocredit*

182 We report no significant difference in the diagnostic accuracy among participants with
183 symptoms irrespective of days since onset, or vaccination status for all Ag-RDTs and
184 swabbing combination (all P values > 0.05). Both Biocredit and Sure-Status Ag-RDTs using
185 both swab types had better sensitivities on detecting SARS-CoV-2 antigens on individuals
186 with Ct values < 25 than >30 ($P = 0.029$ in NP and $P = 0.047$ in AN for Sure-Status and $P =$
187 0.018 and $P = 0.001$ for Biocredit).

188 The RNA copy numbers per mL (RNA copies/mL) of RT-PCR NP swabs was calculated and
189 statistically higher viral loads were obtained for the Sure-Status cohort than Biocredit (Fig 1)
190 measured by Kruskal–Wallis ($P = 0.006$). We determined the 50% and 95% limits of detection
191 (LoD) for both Ag-RDT and swab types based on a logistic regression model (Fig 2). For Sure-
192 Status, the RNA copies/mL for 50% LoD and 95% LoD were 2.4×10^4 and 3.16×10^8 for NP
193 specimen and 3.4×10^4 and 7.94×10^7 for AN swabs. For Biocredit, the RNA copies/mL for
194 LoD50 and LoD95 were 9.12×10^3 and 3.02×10^8 for NP specimen and 1.12×10^5 and $6.76 \times$
195 10^6 for AN swabs. Although the LoD95 was better for AN swabs for both Ag-RDT brands
196 (3.98 for Sure-Status and 44.67 for Biocredit), there was no statistical difference on LODs
197 neither by swab type and Ag-RDT brand (all P values > 0.05).

198 *Quantitative read-out analysis*

199 Quantitative read-out in paired positive AN and NP was more often higher for the NP (40
200 instances higher on NP and four higher on AN in Sure-Status; and 35 instances higher on NP

201 and 12 higher on AN in Biocredit) and gave significantly higher scores for both Ag-RDT, Sure-
202 Status ($P = 0.007$) and Biocredit ($P = 0.013$) (Figure 1) measured by Kruskal–Wallis.
203 Additionally, test lines scores were analysed by RNA copies/mL and these had a positive
204 correlation. For Biocredit, strong correlation using AN swabs ($r_p = 0.727$) but moderate using
205 NP swabs ($r_p = 0.591$). For Sure-Status, both swab types had a moderate correlation to viral
206 loads (NP swab $r_p = 0.614$ and AN swab $r_p = 0.661$).

207 **DISCUSSION**

208 This is the first diagnostic clinical evaluation of Sure-Status Ag-RDT and results have shown a
209 satisfactory performance for both AN and NP swabs fulfilling the sensitivity ($\geq 80\%$) and
210 specificity ($\geq 97\%$) outlined in the target product profile (TPP) WHO standards [8]. For
211 Biocredit Ag-RDT, there are five studies to date that have evaluated the performance of NP
212 swabs reporting varied sensitivities from 52% to 85% [15]. In this study we report a higher
213 sensitivity (81.2% ,CI95%73.1-87.7%) and specificity (99.0% ,CI95%94.7-86.5%) of the
214 Biocredit Ag-RDT fulfilled the WHO standards using NP swab but underperformed in the
215 sensitivity (79.5%, CI95% 71.3-86.3%) criteria when using AN.

216 Results presented here demonstrate that AN swabs are equivalent to NP swabs for SARS-
217 CoV-2 Ag-RDT testing giving comparable sensitivities, 50% LoD and 95% LoD for both Ag-
218 RDTs brands evaluated here. Our results supports previous findings where AN and NP swabs
219 were compared for the Ag-RDT Standard-Q (SD Biosensor, Inc., Korea) in Lesotho [6], but we
220 reported a higher sensitivity compared to the 67.3% and 70.2% for AN and NP swabs
221 previously described [6]. Studies on RT-qPCR have found lower sensitivity using AN swabs
222 compared to NP swabs consistently [5]. However, the difference in sensitivity was only
223 significant for patients with viral loads $< 10^3$ copies/mL [16] and this threshold is not

224 relevant to Ag-RDTs of which the limit of detection ranges between 10^4 - 10^8 RNA copies/mL
225 in swabs [11].

226 Quantitative assessment of the test line scores showed that test line intensity was
227 significantly higher on NP swabs than AN swabs. The line intensity is an important
228 component of home testing as studies have shown fainter lines are more difficult to
229 interpret for a lay person, likely due to lower signal intensity [17]. In an user experience
230 home based study, 77.1% of the cases that the participants interpreted wrongly as negative
231 being positive, were weak and moderate positives while only 22.9% were strong positives
232 [17]. The significantly lower intensity of the AN swab compared to NP swab is likely
233 attributed to the differences of SARS-CoV-2 viral loads in the respiratory tract. Studies have
234 found lower viral loads on AN swabs compared to NP swabs [16]. Statistical analysis
235 supported this hypothesis where a positive correlation between viral loads and Ag-RDT test
236 line scores was shown. Further implementation studies on Ag-RDT test results interpretation
237 by patients or within a home testing setting are urgently needed to drive self-testing to
238 scale.

239 This study has several strengths, the use of standardised sampling methods, independent
240 blinded readers, robust statistical analysis, quantitative assessment of Ag-RDT test line
241 results and the evaluation of one approved WHO-EUL Ag-RDT test brands (Sure-Status) and
242 under review (Biocredit). Qualifying it to have high global public health relevance [18].

243 The main limitation of this study is that the AN swabs were always taken last. The order of
244 sample collection could have negatively biased the results obtained for AN swabs caused by
245 a possible sample depletion. However, in the two studies that compared Ag-RDT using AN
246 swabs, the AN swab was collected first and our reported sensitivity and specificity for AN

247 swabs are greater than the previous studies [6,7]. Further, studies on RT-qPCR found lower
248 sensitivity using AN swabs compared to NP swabs [5], even when AN swabs were collected
249 first [15,18,19]. Thereby it is unlikely that the order of the swabs impacted sample
250 availability for AN and NP sampling.

251 In conclusion, this study demonstrates the sensitivity of two SARS-CoV-2 Ag-RDTs using AN-
252 sampling are comparable to that of NP-sampling. AN-sampling can be performed with less
253 training, reduces patient discomfort, and enables scaling up of antigen testing strategies.
254 Test line intensity however is lower when using AN swabs which could influence negatively
255 the interpretation of the Ag-RDT results. Additional studies on Ag-RDTs using AN swabs on
256 self-interpretation by a lay person are needed and further education around how to
257 interpret a positive Ag-RDT to the wider community.

258 **Acknowledgements**

259 Condor steering group: Dr A. Joy Allen, Dr Julian Braybrook, Professor Peter Buckle, Ms
260 Eloise Cook, Professor Paul Dark, Dr Kerrie Davis, Dr Gail Hayward, Professor Adam Gordon,
261 Ms Anna Halstead, Dr Charlotte Harden, Dr Colette Inkson, Ms Naoko Jones, Dr William
262 Jones, Professor Dan Lasserson, Dr Joseph Lee, Dr Clare Lendrem, Dr Andrew Lewington, Ms
263 Mary Logan, Dr Massimo Micocci, Dr Brian Nicholson, Professor Rafael Perera-Salazar, Mr
264 Graham Prestwich, Dr D. Ashley Price, Dr Charles Reynard, Dr Beverley Riley, Professor John
265 Simpson, Dr Valerie Tate, Dr Philip Turner, Professor Mark Wilcox, Dr Melody Zhifang.

266 We would like to acknowledge the participants for volunteering for this study and to the UK
267 National Institute for Health Research Clinical Research Network and the COvid-19 National
268 DiagnOstic Research & evaluation (CONDOR) programme. We also thank the CRN for their
269 support during the study and Daisy Bengey, Rachel Watkins, and Lorna Finch for their help
270 on sample collection and recruitment.

271 **FUNDING**

272 This work was funded as part of FIND's work as co-convener of the diagnostics pillar of the
273 Access to COVID-19 Tools (ACT) Accelerator, including support from Unitaid [grant number:
274 2019-32-FIND MDR], the governments of the Netherlands [grant number: MINBUZA-
275 2020.961444] and from UK Department for International Development [grant number
276 300341-102]. The FALCON study was funded by the National Institute for Health Research,
277 Asthma UK and the British Lung Foundation.

278 **REFERENCES**

- 279 1 FIND. SARS-CoV-2 diagnostic pipeline. <https://www.finddx.org/covid-19/pipeline/>
- 280 2 Center of Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and
281 Testing Clinical Specimens for COVID-19. May 22, 2020.
- 282 3 GOV.UK. New campaign urges public to get tested twice a week. Published Online First:
283 2021. [https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-](https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-twice-a-week)
284 [twice-a-week](https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-twice-a-week)
- 285 4 Péré H, Péré H, Péré H, *et al.* Nasal swab sampling for SARS-CoV-2: A convenient alternative
286 in times of nasopharyngeal swab shortage. *J. Clin. Microbiol.* 2020. doi:10.1128/JCM.00721-
287 20
- 288 5 Zhou Y, OLeary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial
289 detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-Analysis. *PLoS One.*
290 2021. doi:10.1371/journal.pone.0254559
- 291 6 Labhardt, Niklaus D González Fernández L, Katende, Bulemba Muhairwe J, Bresser M, *et al.*
292 Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid
293 antigen testing in Lesotho. *medRxiv* Published Online First: 2022.
294 doi:10.1101/2021.12.29.21268505

- 295 7 Lindner AK, Nikolai O, Kausch F, *et al.* Head-to-head comparison of SARS-CoV-2 antigen-
296 detecting rapid test with self-collected anterior nasal swab versus professional-collected
297 nasopharyngeal swab. *Eur Respir J*
298 2020;**57**:2003961.<http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03961-2020>
- 299 8 (WHO) WHO, R&D Blue Print WH (HQ). Target product profiles for priority diagnostics to
300 support response to the COVID-19 pandemic v.1.0. Published Online First:
301 2020.[https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-](https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1)
302 [priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1](https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1)
- 303 9 GOV.UK. People with a positive lateral flow test no longer required to take confirmatory PCR
304 test. Published Online First: 2021.[https://www.gov.uk/government/news/people-with-a-](https://www.gov.uk/government/news/people-with-a-positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test)
305 [positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test](https://www.gov.uk/government/news/people-with-a-positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test)
- 306 10 World Health Organization (WHO). Prequalification Teams D. Instructions and requirements
307 for Emergency Use Listing (EUL) Submission: In vitro diagnostics detecting SARS-CoV-2 nucleic
308 acid or antigen.
309 [https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6](https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6_NAT-Ag.pdf)
310 [_NAT-Ag.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6_NAT-Ag.pdf)
- 311 11 Cubas-Atienzar, Ana I., Kontogianni K, Edwards T, *et al.* Limit of detection in different
312 matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. *Sci*
313 *Rep* 2021;**11**:1–8. doi:<https://doi.org/10.1038/s41598-021-97489-9>
- 314 12 Schober P, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. *Anesth*
315 *Analg* Published Online First: 2018. doi:10.1213/ANE.0000000000002864
- 316 13 GOV.UK. Vaccinations in the UK. Coronavirus UK.
317 2022.<https://coronavirus.data.gov.uk/details/vaccinations>
- 318 14 Mahase E. Covid-19: Is the UK heading for another omicron wave? *BMJ* 2022;**376**.

319 doi:<https://doi.org/10.1136/bmj.o738>

320 15 Brümmer LE, Katzenschlager S, Gaeddert M, *et al.* Accuracy of novel antigen rapid diagnostics
321 for SARS-CoV-2: A living systematic review and meta-analysis. *PLoS Med.* 2021.

322 doi:[10.1371/journal.pmed.1003735](https://doi.org/10.1371/journal.pmed.1003735)

323 16 Callahan C, Lee R, Lee G, *et al.* Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral
324 Loads. *medRxiv* 2020.

325 17 Jing M, Bond R, Robertson LJ, *et al.* User experience of home-based AbC-19 SARS-CoV-2
326 antibody rapid lateral flow immunoassay test. *Sci Rep* 2022;**12**:1173. doi:[10.1038/s41598-](https://doi.org/10.1038/s41598-022-05097-y)
327 [022-05097-y](https://doi.org/10.1038/s41598-022-05097-y)

328 18 World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic — Emergency
329 Use Listing Procedure (EUL) open for IVDs. Prequalification Med. Prod. (IVDs, Med. Vaccines
330 Immun. Devices, Vector Control. [https://extranet.who.int/pqweb/vitro-](https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic---emergency-use-listing-procedure-eul-open)
331 [diagnostics/coronavirus-disease-covid-19-pandemic---](https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic---emergency-use-listing-procedure-eul-open)
332 [emergency-use-listing-procedure-eul-](https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic---emergency-use-listing-procedure-eul-open)
[open](https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic---emergency-use-listing-procedure-eul-open)

333 19 Hanson KE, Barker AP, Hillyard DR, *et al.* Self-collected anterior nasal and saliva specimens
334 versus health care worker-collected nasopharyngeal swabs for the molecular detection of
335 SARS-CoV-2. *J Clin Microbiol* Published Online First: 2020. doi:[10.1128/JCM.01824-20](https://doi.org/10.1128/JCM.01824-20)

336 20 Tu Y-P, Jennings R, Hart B, *et al.* Swabs Collected by Patients or Health Care Workers for
337 SARS-CoV-2 Testing. *N Engl J Med* Published Online First: 2020. doi:[10.1056/nejmc2016321](https://doi.org/10.1056/nejmc2016321)

338


339

340

341

342

343




344

345 **Figure 1.** Boxplot of the SARS-CoV-2 viral load distribution of the RT-qPCR NP swabs used as
346 reference standard for the participants enrolled for Sure-Status and Biocredit Ag-RDT evaluation.
347 The whiskers show the maximum and minimum values and the vertical line the median. Asterisks
348 indicate statistical significance between AN and NP swab types.

349


350

351



352
353 **Figure 2.** Limit of detection analyses of upper-respiratory samples positive by RT-qPCR for Sure-
354 Status and Biocredit using AN and NP swabs. The log₁₀ RNA copies on the x axis were plotted
355 against a positive (1.0) or negative (0.0) Ag-RDT result on the y axis. Green (Sure-Status) and purple
356 (Biocredit) curves show logistic regressions of the viral load on the Ag-RDT result; vertical dashed
357 lines indicate log₁₀ RNA copies subjected to the test at which 50% and 95% LoD of the samples are
358 expected positive based on the regression results. No significant differences were observed.

359
360



361
362 **Figure 3.** Boxplot of the scores of the test lines for both Ag-RDT Sure-Status and Biocredit using AN
363 and NP swabs. The whiskers show the maximum and minimum values and the vertical line the
364 median. Asterisks indicate statistical significance between AN and NP swab types.

365

366

367

368

369

370

371

372

373

374

375 **Table 1.** Demographics of the population of study for Sure-Status and Biocredit cohorts

	Sure-Status	Biocredit	All
Total	372	232	604
Age [mean (min-max), IQR]	43 (18-81), 33-53	43 (18-78), 33-51	43 (18-81), 33-52
Gender [%F, (n/N)] IQR]	57%, (211/372)	59%, (137/232)	58%, (348/602)
Triple vaccinated (n, %)	NA*	143 (61.6%)	143 (23.8%)
Double vaccinated (n, %)	314 (84.4%)	74 (40%)	388 (64.4%)
Partially vaccinated (n, %)	29 (7.8%)	4 (1.7%)	33 (5.5%)
Not vaccinated (n, %)	27 (7.3%)	10 (4.3%)	37 (6.2%)
Vaccination not disclosed (n, %)	2 (0.5)	1 (0.3%)	3 (0.5%)
Days symptoms onset [median (IQR); N]	2 (1-3), 371	2 (1-3), 232	2 (1-3), 601
Days 0-3 (n, %)	304, 81.7%	186, 80.2%	490, 81.1%
Days 4-7 (n, %)	56, 15.1%	41, 17.7%	97, 16.1%
Days 8+ (n, %)	10, 2.7%	5, 2.2%	15, 2.5%
RT-qPCR SARS-CoV-2 Positivity [%, (n/N)]	32.1%, (119/371)	53.7%, (122/227)	40.3% (241/598)
Symptom [total n (%), in RT-qPCR positive n (%)]			
Cough	248 (66.7%), 73 (61.3%)	139 (60.0%), 71 (58.2%)	387 (64.3%), 144 (60.0%)
Sore throat	129 (34.7%), 34 (28.6%)	103 (44.4%), 56 (45.9%)	232 (38.5%), 90 (37.4%)
Headache	123 (33.1%), 57 (47.9%)	80 (34.5%), 45 (36.9%)	203 (33.7%), 102 (42.3%)
Fever	106 (28.5%), 30 (25.2%)	54 (23.3%), 28 (22.9%)	160 (26.6%), 58 (24.1%)
Body aches	41 (11.0%), 21 (17.7%)	39 (16.8%), 29 (23.8%)	80 (13.3%), 51 (21.2%)
Runny nose	39 (13.2%), 20 (16.8%)	41 (17.7%), 31 (25.4%)	80 (13.3%), 51 (21.2%)
Loss taste	48 (12.9%), 19 (16.0%)	19 (8.2%), 10 (8.2%)	67 (11.1%), 29 (12.0%)
Loss smell	29 (7.8%), 9 (7.6%)	14 (6.0%), 7 (5.7%)	43 (7.1%), 16 (6.6%)
Chest pain	18 (4.8%), 7 (5.9%)	12 (5.2%), 8 (6.6%)	30 (5.0%), 15 (6.2%)
Fatigue	13 (3.5%), 4 (3.4)	17 (7.3%), 10 (8.2%)	30 (5.0%), 14 (5.8%)
Shortness of breath/tight chest	13 (3.5%), 3 (2.5%)	9 (3.9%), 5 (4.1%)	22 (3.6%), 15 (6.2%)
Vomiting	11 (3%), 5 (4.2%)	2 (8.6%), 2 (1.6%)	13 (2.2%), 7 (2.9%)
Diarrhoea	9 (2.4%), 3 (2.5%)	3 (13%), 3 (2.5%)	12 (2.0%), 6 (2.5%)
Abdominal pain	6 (1.6%), 3 (2.5%)	1 (0.4%), 1 (0.8%)	7 (1.2%), 4 (1.7%)
Rash	3 (0.8%), 0 (0.0%)	1 (0.4%), 1 (0.8%)	4 (0.6%), 1 (0.4%)
Confusion	1 (0.3%), 0 (0.0%)	0 (0%)	1 (0.2%), 0 (0%)
Other	159 (42.7%), 68 (57.4%)	134 (57.8%), 85 (69.7%)	293 (48.7%), 153 (63.5%)

376 *Participants were enrolled before booster rolled out in the UK

377

378

379

380

381 **Table 2.** Clinical sensitivity and specificity of Sure-Status and Biocredit using NP and Nasal Swab

All Ct values	TP	FP	TN	FN	Sensitivity	Specificity	NPV	PPV
Sure-Status	200	5	494	38	83.9 (78.3-88.1)	99.0 (97.7-99.7)	92.7(90.5-94.4)	97.6 (94.3-98.9)
NP swab	99	2	249	20	83.2 (75.2-89.4)	98.8 (96.5-99.6)	91.7 (88.4-94.2)	97.1 (91.44-99.03)
AN swab	101	2	245	18	84.0 (76.2-90.1)	99.2 (97.0-99.8)	92.8 (89.5-95.1)	98.0 (92.62-99.5)
Biocredit	196	1	209	48	80.3 (74.8-85.1)	99.1 (95.0-99.9)	81.3(77.2-84.9)	99.5 (96.5-100)
NP swab	99	1	104	23	81.2 (73.1-87.7)	99.0 (94.7-86.5)	81.9 (73.99-85.2)	99.0 (93.4-99.9)
AN swab	97	0	105	25	79.5 (71.3-86.3)	100 (96.5-100)	80.8 (74.8-85.6)	100 (100-100)
All NP	198	4	353	43	82.2 (76.7-86.8)	98.9 (97.2-99.7)	89.1 (86.2-91.5)	98.0 (94.9-99.2)
All AN	198	2	350	43	82.2 (76.7-86.8)	99.4 (97.9-99.9)	89.1 (86.2-91.5)	99.0 (96.1-99.8)

